MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2023 International Congress

    Sympathetic tone abnormalities in subjects at risk for Parkinson’s Disease without evidence of nigrostriatal neurodegeneration: a multimodal biomarker study

    M. Gregorio, H. Maghzi, G. Obialisi, E. Hogg, C. Malatt, E. Tan, H. Pomeroy, R. Artal, M. Shehata, B. Renner, P. Sati, G. Pagano, M. Tagliati (Los Angeles, USA)

    Objective: To study autonomic dysfunction in subjects with idiopathic REM sleep behavior disorder (iRBD) and at least one pre-motor symptom of Parkinson's disease (PD). Background:…
  • 2023 International Congress

    Testing gene-environment interaction in Parkinson’s disease (PD) using whole-genome sequencing of pesticide-exposed cohorts.

    S. Goldman, J. Kaye, M. Traglia, R. Swanson, L. Lima, S. Finkbeiner, C. Tanner (San Francisco, USA)

    Objective: To identify interactions of specific pesticides with genetic loci to find causal variants for PD using gene burden analysis (BA). Background: Pesticide exposure is…
  • 2023 International Congress

    Oculomotor parameters measured during free viewing of video differentiate Parkinson’s disease from progressive supranuclear palsy

    H. Riek, B. White, D. Brien, B. Coe, C. Fearon, S. Arnott, D. Beaton, M. Binns, S. Black, E. Finger, A. Frank, D. Grimes, A. Lang, W. Lou, C. Marras, M. Masellis, P. Mclaughlin, J. Orange, A. Peltsch, A. Roberts, T. Steeves, K. Sunderland, B. Tan, D. Tang-Wai, C. Tartaglia, D. Munoz (Kingston, Canada)

    Objective: Characterize oculomotor phenotypes comprised of saccade, pupil, and blink behaviour for progressive supranuclear palsy (PSP) and Parkinson’s disease (PD) with differing degrees of cognitive…
  • 2023 International Congress

    Development and Evaluation of a Digital Resource Library for Arkansans with Parkinson Disease and Their Caregivers

    S. Dhall, A. Diamond, T. Virmani, R. Sloan, T. Burrow, J. Chacko, C. Fullen, T. Reckling, J. Holton, H. Pickett, H. Petersen, K. Coleman, D. Mcclendon, D. Chandler, E. Echols, C. Gauss, K. Donovan, S. Parveen, R. Dhall (Little Rock, USA)

    Objective: To develop and evaluate impact of a Digital Resource Library (DRL) to address unmet needs for disease state education of People with PD (PwP)…
  • 2023 International Congress

    Novel application of the Timed Up and Go Scale as a reliable tool to measure functional improvement and fall prevention after inpatient Parkinson’s Disease specific rehabilitation for advanced stages of PD

    M. Mccrossin, L. Rubin, C. Claro, A. Persaud, E. Finlay, A. Sturman, D. Barreto, A. John, M. Tursi, A. Di Rocco (Glen Cove, USA)

    Objective: To determine whether the “Timed Up and Go” (TUG) scale can be effectively utilized in patients with advanced Parkinson’s disease (PD) as an outcome…
  • 2023 International Congress

    Correlations between bradykinesia and acoustic speech variables in advanced Parkinson’s Disease

    F. Cavallieri, G. Di Rauso, A. Gessani, C. Budriesi, V. Fioravanti, S. Contardi, E. Menozzi, S. Pinto, E. Moro, F. Antonelli, F. Valzania (Reggio Emilia, Italy)

    Objective: To find the presence of possible correlations between upper extremity bradykinesia and speech variables in different medication conditions in a cohort of advanced Parkinson’s…
  • 2023 International Congress

    A multiple-dose thorough QT study to evaluate the effect of ampreloxetine on cardiac repolarization in healthy subjects

    M. Borin, J. Kanodia, R. Graham, A. Lo, B. Zheng, D. Bourdet (South San Francisco, USA)

    Objective: To characterize the effect of therapeutic and supratherapeutic doses of ampreloxetine on cardiac repolarization in healthy subjects. Background: Ampreloxetine is a potent NE reuptake…
  • 2023 International Congress

    Association between supine hypertension and plasma free triiodothyronine in drug-naïve Parkinson’s disease

    T. Umehara, T. Kokubu, J. Takahashi, T. Shiraishi, T. Sato, A. Onda, I. Iguchi (Tokyo, Japan)

    Objective: We aimed to clarify the association between thyroid hormone levels and supine hypertension (SH) in patients with early Parkinson’s disease (PD). Background: Increasing evidence…
  • 2023 International Congress

    Influence of square-stepping exercise on brain activation in older adults with cognitive frailty

    YH. Wang, RY. Wang, YR. Yang (Taipei, Taiwan)

    Objective: To investigate the brain activity induced by square-stepping exercise (SSE), as well as the relationships between brain activity change and SSE performance in older…
  • 2023 International Congress

    The effect of taVNS on gait in advanced Parkinsons disease – a double blind, sham controlled motion sensors study in 30 patients

    V. van Midden, Z. Pirtošek, U. Simončič, M. Kojović (Ljubljana, Slovenia)

    Objective: In this double blind, sham controlled study on 30 advanced Parkinson’s disease (aPD) patients we used inertial motion sensors (IMS) to characterize the effect…
  • « Previous Page
  • 1
  • …
  • 50
  • 51
  • 52
  • 53
  • 54
  • …
  • 186
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • #23285 (not found)
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley